Glycation of human serum albumin in diabetes: Impacts on the structure and function

Current Medicinal Chemistry

Volumn 22, Issue 1, 2015, Pages 4-13

  Cao, Hui ^a,b   Chen, Tingting ^a   Shi, Yujun ^a  

^a NANTONG UNIVERSITY   (China)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Diabetes; Glycation; Plasma proteins; Protein binding; Serum albumin; Structure and function

Indexed keywords

FLAVONOID; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; HUMAN SERUM ALBUMIN; PLANT MEDICINAL PRODUCT; REACTIVE OXYGEN METABOLITE; BIOLOGICAL PRODUCT; GLYCOSYLATED SERUM ALBUMIN; MOLECULAR LIBRARY; PROTEIN BINDING; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SERUM ALBUMIN;

ARTICLE; BINDING AFFINITY; CALORIMETRY; CELL FUNCTION; CELL PROLIFERATION; CRYSTAL STRUCTURE; CYCLIC POTENTIOMETRY; DIABETES MELLITUS; ELECTROCHEMICAL ANALYSIS; ENZYMATIC ASSAY; FLUORESCENCE; FLUORESCENCE SPECTROSCOPY; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; LIGAND BINDING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; RAMAN SPECTROMETRY; RECEPTOR BINDING; THERMOSTABILITY; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; MOLECULAR LIBRARY; PATHOLOGY;

BIOLOGICAL PRODUCTS; DIABETES MELLITUS, TYPE 2; HUMANS; NADPH OXIDASE; PROTEIN BINDING; SERUM ALBUMIN; SMALL MOLECULE LIBRARIES;

EID: 84929086989     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140912155738     Document Type: Article

References (108)

1. Wild, S.; Roglic, G.; Green, A.; Sicree R.; King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27, 1047-1053.
2. International Diabetes Federation Task Force on Diabetes Health Economy. Diabetes heath economics: facts, figures, and forecasts. Brussels: International Diabetes Federation, 1997.
3. World Health Organization. Diabetes fact sheet no. 312, March 2013 [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
4. Rondeau, P.; Bourdon, E. The glycation of albumin: Structural and functional impacts. Biochimie., 2011, 93, 645-658.
5. Barnaby, O. S.; Cerny, R. L.; Clarke, W.; Hage, D. S. Comparison of modification sites formed on human serum albumin at various stages of glycation. Clin. Chim. Acta., 2011, 412, 277-285.
6. Thornalley, P. J.; Langborg, A.; Minhas, H. S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J., 1999, 344, 109-116.
7. Bai, X.; Wang, Z. J.; Huang, C. C.; Wang, Z.; Chi. L. L. Investigation of non-enzymatic glycosylation of human serum albumin using ion trap-time of flight mass spectrometry. Molecules, 2012, 17, 8782-8794.
8. Barnaby, O. S.; Cerny, R. L.; Clarke, W.; Hage, D. S. Quantitative analysis of glycation patterns in human serum albumin using 16O/18O-labeling and MALDI-TOF MS. Clin. Chim. Acta., 2011, 412, 1606-1615.
9. Wang, Y.; Yu, H. Y.; Shi, X. L.; Luo, Z. P.; Lin, D. H.; Huang, M. D. Structural mechanism of ring-opening reaction of glucose by human serum albumin. J. Biol. Chem., 2013, 288, 15980-15987.
10. Bhonsle, H. S.; Korwar, A. M.; Kote, S. S.; Golegaonkar, S. B.; Chougale, A. D.; Shaik, M. L.; Dhande, N. L.; Giri, A. P.; Shelgikar, K. M.; Boppana, R.; Kulkarni, M. J. Low plasma albumin levels are associated with increased plasma protein glycation and HbA1c in diabetes. J. Proteome Res., 2012, 11, 1391-1396.
11. Zhang, Q. B.; Tang, N.; Schepmoes, A. A.; Phillips, L. S.; Smith, R. D.; Metz, T. O. Proteomic profiling of nonenzymatically glycated proteins in human plasma and erythrocyte membranes. J. Proteome Res., 2008, 7, 2025-2032.
12. Koga, M.; Murai, J.; Saito, H.; Kasayama, S. Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes. Diabetes Care, 2010, 33, 270-272.
13. Hashimoto, K.; Osugi, T.; Noguchi, S.; Morimoto, Y.; Wasada, K.; Imai, S.; Waguri, M.; Toyoda, R.; Fujita, T.; Kasayama, S.; Koga, M. A1C but not serum glycated albumin is elevated because of iron deficiency in late pregnancy in diabetic women. Diabetes Care, 2010, 33, 509-511.
14. Baraka-Vidot, J.; Guerin-Dubourg, A.; Dubois, F.; Payet, B.; Bourdon, E.; Rondeau, P.; et al. New insights into deleterious impacts of in vivo glycation on albumin antioxidant activities. Biochim. Biophys. Acta., 2013, 1830, 3532-3541.
15. Vlassopoulos, A.; Lean, M. E. J.; Combet, E. Role of oxidative stress in physiological albumin glycation: A neglected interaction. Free Radic. Biol. Med., 2013, 60, 318-324.
16. Suzuki, S.; Koga, M.; Niizeki, N.; Furuya, A.; Takahashi, H.; Matsuo, K.; Tanahashi1, Y.; Kawata1, Y.; Asai1, H.; Tsuchida1, E.; Nohara1, F.; Okamoto1, T.; Nagaya1, K.; Azuma, H. Glycated albumin is lower in infants than in adults and correlated with both age and serum albumin. Pediatric Diabetes, 2013, 14, 25-30.
17. Peacock, T. P.; Shihabi, Z. K.; Bleyer, A. J.; Dolbare, E. L.; Byers, J. R.; Knovich, M. A.; Calles-Escandon, J.; Russell, G. B.; Freedman, B. I. Comparison of glycated albumin and hemoglobin A (1c) levels in diabetic subjects on hemodialysis. Kidney Int., 2008, 73, 1062-1068.
18. Kumeda, Y.; Inaba, M.; Shoji, S.; Ishimura, E.; Inariba, H.; Yabe, S.; Okamura, M.; Nishizawa, Y. Significant correlation of glycated albumin, but not glycated haemoglobin, with arterial stiffening in haemodialysis patients with type 2 diabetes. Clin. Endocrinol., 2008, 69, 556-561.
19. Cohen, M. P.; Ziyadeh, F. N.; Chen, S. Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. J. Lab. Clin. Med., 2006, 147, 211-219.
20. Li, Y. Z.; Wang, S. X. Glycated albumin activates NADPH oxidase in rat mesangial cells through up-regulation of p47phox. Biochem. Biophys. Res. Commun., 2010, 397, 5-11.
21. Rodiño-Janeiro, B. K.; González-Peteiro, M.; Ucieda-Somoza, R.; González-Juanatey, J. R.; Álvarez, E. Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: molecular correlate of diabetic vasculopathy. Diabetes Metab. Res. Rev., 2010, 26, 550-558.
22. Rubenstein, D. A.; Maria, Z.; Yin, W. Glycated albumin modulates endothelial cell thrombogenic and inflammatory responses. J. Diabetes Sci. Technol., 2011, 5, 703-713.
23. Bala, K.; Gomes, J.; Gohil, N. K. Interaction of glycated human serum albumin with endothelial cells in a hemodynamic environment: structural and functional correlates. Mol. BioSyst., 2011, 7, 3036-3041.
24. Balaz, K.; Gohil, N. K. Interaction of glycated protein and DFO mimicked hypoxia in cellular responses of HUVECsw. Mol. Bio-Syst., 2012, 8, 2657-2663.
25. Shafi, T.; Sozio, S. M.; Plantinga, L. C.; Jaar, B. G.; Kim, E. T.; Parekh, R. S.; Steffes, M. W.; Powe, N. R.; Coresh, J.; Selvin E. Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. Diabetes Care, 2013, 36, 1522-1533.
26. Schalkwijk, C. G.; Miyata, T. Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics. Amino Acids, 2012, 42, 1193-1204.
27. Pu, L. J.; Lu, L.; Xu X. W.; Zhang R. Y.; Zhang, Q.; Zhang, J. S.; Hu, J.; Yang, Z. K.; Ding, F. H.; Chen, Q. J.; Lou, S.; Shen, J.; Fang, D. H.; Shen, W. F. Value of serum glycated albumin and highsensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovascul. Diabetol., 2006, 5, 27-33.
28. Gross, M. L.; Piecha, G.; Bierhaus, A.; Hanke, W.; Henle, T.; Schirmacher, P.; Ritz, E. Glycated and carbamylated albumin are more "nephrotoxic" than unmodified albumin in the amphibian kidney. Am. J. Physiol. Renal. Physiol., 2011, 301, F476-F485.
29. Moheimani, F.; Morgan, P. E.; Van Reyk, D. M.; Davies, M. J. Deleterious effects of reactive aldehydes and glycated proteins on macrophage proteasomal function: Possible links between diabetes and atherosclerosis. Biochimica et Biophysica Acta., 2010, 1802, 561-571.
30. Londoño, I.; Gingras, D.; Bendayan, M. Circulating glycated albumin and glomerular anionic charges. Experiment Diab. Res., 2003, 4, 83-92.
31. Sartori, A.; Prates E. A. G.; Monteiro, H. P. Glycated albumin by methylglyoxal promotes oxidative stress and dysregulation of PI3K/Akt/Bad survival signaling pathway in the insulin-producing cells MIN-6. SFRBM, 2012, S98.
32. Hom, F. G.; Ettinger, B.; Lin, M. J. Comparison of serum fructosamine vs glycohemoglobin as measures of glycemic control in a large diabetic population. Acta. Diabetol., 1998, 35, 48-51.
33. Ko, G. T. C.; Chan, J. C. N.; Yeung, V. T. F.; Chow, C. C.; Tsang, L. W.; Li, J. K.; So, W. Y.; Wai, H. P.; Cockram, C. S. Combined Use of a Fasting Plasma Glucose Concentration and HbA1c or Fructosamine Predicts the Likelihood of Having Diabetes in High-Risk Subjects. Diabetes Care, 1998, 21, 1221-1225.
34. American Diabetes Association. Summary of Revisions for the 2010 Clinical Practice Recommendations. Diabetes Care, 2010, 33, S4-S10.
35. Peacock, T. P.; Shihabi, Z. K.; Bleyer, A. J.; Dolbare, E. L.; Byers, J. R.; Knovich, M. A.; Calles-Escandon, J.; Russell, G. B.; Freedman, B. I. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int., 2008, 73, 1062-1068.
36. Rondeau, P.; Bourdon, E. The glycation of albumin: Structural and functional impacts. Biochimie., 2011, 93, 645-658.
37. Yoshiuchi, K.; Matsuhisa, M.; Katakami, N.; Nakatani, Y.; Sakamoto, K.; Matsuoka, T.; Umayahara, Y.; Kosugi, K.; Kaneto, H.; Yamasaki, Y.; Hori, M. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr. J., 2008, 55, 503-507.
38. Roohk, H. V.; Zaidi, A. R. A review of glycated albumin as an intermediate glycation index for controlling diabetes. J. Diabetes Sci. Technol., 2008, 6, 1114-1121.
39. Morais, M. P. P.; Mackay, J. D.; Bhamra, S. K.; Buchanan, J. G.; James, T. D.; Fossey J. S.; Jean, M. H.; Van Den, E. Analysis of protein glycation using phenylboronate acrylamide gel electrophoresis. Proteomics, 2010, 10, 48-58.
40. Jackson, A. J.; Anguizola, J.; Pfaunmiller, E. L.; Hage, D. S. Use of entrapment and high-performance affinity chromatography to compare the binding of drugs and site-specific probes with normal and glycated human serum albumin. Anal. Bioanal. Chem., 2013, 405, 5833-5841.
41. Zhernovaya, O. S.; Tuchin, V. V.; Meglinski, I. V. Monitoring of blood proteins glycation by refractive index and spectral measurements. Laser Phys. Lett., 2008, 5, 460-464.
42. Brancia F. L.; Bereszczak J. Z.; Lapolla A.; Fedele D.; Baccarin L.; Seraglia R. Traldi P. Comprehensive analysis of glycated human serum albumin tryptic peptides by off-line liquid chromatography followed by MALDI analysis on a time-of-flight/curved field reflectron tandem mass spectrometer. J. Mass Spectrom., 2006, 41, 1179-1185.
43. Nakamoto, I.; Morimoto, K. Correlation between molecular weight of plasma albumin determined with mass spectrometry and glycation indices in factory workers. Environ. Health Prev. Med., 2004, 9, 63-66.
44. Barnaby, O.; Wa, C.; Cerny, R. L.; Clarke W.; Hage, D. S. Quantitative analysis of human serum albumin using 16O/18O-labeling and matrix-assisted maser desorption/ionization time-of-flight mass spectrometry. Clin. Chim. Acta, 2010, 411, 1102-1110.
45. Wa, C. L.; Cerny, R. L.; Clarke, W. A.; Hage, D. S. Characterization of glycation adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chim. Acta, 2007, 385, 48-60.
46. Bai, X.; Wang, Z. J.; Huang, C. C.; Wang, Z.; Chi, L. L. Investigation of non-enzymatic glycosylation of human serum albumin using ion trap-time of flight mass spectrometry. Molecules, 2012, 17, 8782-8794.
47. Morais, M. P. P.; Marshall, D.; Flower, S. E.; Caunt, C. J.; James, T. D.; Williams, R. J.; Waterfield, N. R.; Van Den Elsen, J. M. H. Analysis of protein glycation using fluorescent phenylboronate gel electrophoresis. Sci. Rep., 2013, 3, 1437-1443.
48. Abidin, D.; Liu, L. M.; Dou, C.; Datta, A.; Yuan, C. An improved enzymatic assay for glycated serum protein. Anal. Methods., 2013, 5, 2461-2469.
49. Lapolla, A.; Molin, L.; Traldi, P. Protein glycation in diabetes as determined by mass spectrometry. Int. J. Endocrinol., 2013, Article Number: 412103.
50. Ledesma-Osuna, A. I.; Ramos-Clamont, G.; Vázquez-Moreno, L. Characterization of bovine serum albumin glycated with glucose, galactose and lactose. Acta. Biochim. Pol., 2008, 55, 491-497.
51. Dingari, N. C.; Horowitz, G. L.; Kang, J. W.; Dasari, R. R.; Barman, I. Raman spectroscopy provides a powerful diagnostic tool for accurate determination of albumin glycation. PLoS ONE, 2012, 7, e32406.
52. Frolov, A.; Hoffmann, R. Identification and relative quantification of specific glycation sites in human serum albumin. Anal. Bioanal. Chem., 2010, 397, 2349-2356.
53. Zhang Q.; Schepmoes A. A.; Brock J. W. C.; Wu, S.; Moore, R. J.; Purvine, S. O.; Baynes, J. W.; Smith, R. D.; Metz, T. O. Improved methods for the enrichment and analysis of glycated peptides. Anal. Chem., 2008, 80, 9822-9829.
54. Mohamadi-Nejad, A.; Moosavi-Movahedi, A. A.; Safarian, S.; Naderi-Manesh, M. H.; Ranjbar, B.; Farzami, B.; Mostafavie, H.; Larijanif, M. B.; Hakimelahi, G. H. The thermal analysis of nonezymatic glycosylation of human serum albumin: differential scanning calorimetry and circular dichroism studies. Thermochim. Acta, 2002, 389, 141-151.
55. Indurthi, V. S. K.; Leclerc, E.; Vetter, S. W. Interaction between glycated serum albumin and AGE-receptors depends on structural changes and the glycation reagent. Arch. Biochem. Biophy., 2012, 528, 185-196.
56. Daneshegar, P.; Moosavi-Movahedi, A. A.; Norouzi, P.; Ganjali, M. R.; Farhadi, M.; Sheibani, N. Characterization of paracetamol binding with normal and glycated human serum albumin assayed by a new electrochemical method. J. Braz. Chem. Soc., 2012, 23, 315-321.
57. Baraka-Vidot, J.; Guerin-Dubourg, A.; Bourdon, E.; Rondeau, P. Impaired drug-binding capacities of in vitro and in vivo glycated albumin. Biochimie, 2012, 94, 1960-1967
58. Shaklais, N.; Garlick, R. L.; Bunn, H. F. Nonenzymatic glycosylation of human serum albumin alters its conformation and function. J. Biol. Chem., 1984, 259, 3812-3817.
59. Sattarahmady, N.; Moosavi-Movahedi, A. A.; Habibi-Rezaei, M. A biophysical comparison of human serum albumin to be glycated in vivo and in vitro. J. Med. Biochem., 2011, 30, 5-10.
60. Guerin-Dubourg, A.; Catan, A.; Bourdon, E.; Rondeau, P. Structural modifications of human albumin in diabetes. Diab. Metab., 2012, 38, 171-178.
61. Bohlooli, M.; Moosavi-Movahedi, A. A.; Taghavia, F.; Maghami, P.; Saboury, A. A.; Moosavi-Movahedi, Z.; Farhadi, M.; Hong, J.; Sheibani, N.; Habibi-Rezaei, M. Investigation of thermal reversibility and stability of glycated human serum albumin. Int. J. Biol. Macromol., 2013, 62, 358-364.
62. Dostalek, M.; Akhlaghi, F.; Puzanovova, M. Effect of Diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin. Pharmacokinet., 2012, 51, 481-499.
63. Dostalek, M.; Akhlaghi, F.; Puzanovova, M. Effect of Diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin. Pharmacokinet., 2012, 51, 481-499.
64. Xiao, J. B. Polyphenol-plasma proteins interaction: its nature, analytical techniques, and influence on bioactivities of polyphenols. Curr. Drug Metab., 2013, 14, 367-368.
65. Wang, Y. L.; Zhao, Y.; Yang, F.; Yuan, Y. M.; Wang, H.; Xiao J. B. Influences of glucose on the dietary hydroxyflavonoids-plasma proteins interaction. J. Agric. Food Chem., 2012, 60, 12116-12221.
66. Xiao, J. B.; Kai, G. Y. A review of dietary polyphenol-plasma protein interactions: Characterization, influence on the bioactivity, and structure-affinity relationship. Crit. Rev. Food Sci. Nutr., 2012, 52, 85-101.
67. Xiao, J. B.; Chen, T. T.; Cao, H.; Chen, L. S.; Yang, F. Molecular property-affinity relationship of flavanoids and flavonoids for human serum albumin in vitro. Mol. Nutr. Food Res., 2011, 55, 310-317.
68. Xiao, J. B.; Zhao, Y. R.; Wang, H.; Yuan, Y. M.; Yang, F.; Zhang, C.; Yamamoto, K. Non-covalent interaction of dietary polyphenols with common human plasma proteins. J. Agric. Food Chem., 2011, 59, 10747-10754.
69. Xiao, J. B.; Huo, J. L.; Yang, F.; Chen, X. Q. Non-covalent interaction of dietary polyphenols with bovine hemoglobin in vitro: Molecular structure/property-affinity relationship aspects. J. Agric. Food Chem., 2011, 59, 8484-8490.
70. Xiao, J. B.; Cao, H.; Wang, Y. F.; Yamamoto, K.; Wei, X. L. Structureaffinity relationship of flavones on binding to serum albumins: Effect of hydroxyl groups on ring A. Mol. Nutr. Food Res., 2010, 54, S253-S260.
71. Oettl, K.; Stauber, R. E. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br. J. Pharmacol., 2007, 151, 580-590.
72. Day, J. F.; Thorpe, S. R.; Baynes, J. W. Nonenzymatically glucosylated albumin: in vitro preparation and isolation from normal human serum. J. Biol. Chem., 1979, 254, 595-597.
73. Ruiz-Cabello, F.; Erill, S. Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clin. Pharmacol. Ther., 1984, 36, 691-695.
74. Worner, W.; Preissner, A.; Rietbrock, N. Drug-protein binding kinetics in patients with type I diabetes. Eur. J. Clin. Pharmacol., 1992, 43, 97-100.
75. Kearns, G. L.; Kemp, S. F.; Turley C. P., Nelson, D. L. Protein binding of phenytoin and lidocaine in pediatric patients with type I diabetes mellitus. Dev. Pharmacol. Ther., 1988, 11, 14-23.
76. Kemp, S. F.; Kearns, G. L.; Turley, C. P. Alteration of phenytoin binding by glycosylation of albumin in IDDM. Diabetes, 1987, 36, 505-509.
77. Trovik T. S.; Jaeger R.; Jorde, R.; Ingebretsen, O.; Sager, G. Plasma protein binding of catecholamines, prazosin and propranolol in diabetes mellitus. Eur. J. Clin. Pharmacol., 1992, 43, 265-268.
78. Trovik, T. S.; Jaeger, R.; Jorde, R.; Sager, G. Reduced sensitivity to beta-adrenoceptor stimulation and blockade in insulin dependent diabetic patients with hypoglycaemia unawareness. Br. J. Clin. Pharmacol., 1994, 38, 427-432.
79. Reidenberg, M. M.; Drayer, D. E. Alteration of drug-protein binding in renal disease. Clin. Pharmacokinet., 1984, 9(Suppl. 1), 18-26.
80. Keller F.; Maiga M.; Neumayer H. H.; Lode H.; Distler A. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur. J. Drug Metab. Pharmacokinet., 1984, 3, 275-282.
81. Zini, R.; Riant, P.; Barre, J.; Tillement J. P. Disease-induced variations in plasma protein levels: implications for drug dosage regimens (part I). Clin. Pharmacokinet., 1990, 19, 147-159.
82. Okabe, N.; Hashizume, N. Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism. Biol. Pharm. Bull., 1994, 17, 16-21.
83. Koizumi, K.; Ikeda, C.; Ito, M.; Suzuki, J.; Kinoshita, T.; Yasukawa, K.; Hanai, T. Influence of glycosylation on the drug binding of human serum albumin. Biomed. Chromatogr., 1998, 12, 203-210.
84. Hanai, T.; Koseki, A.; Yoshikawa, R.; Ueno, M., Kinoshita, T.; Homma, H. Prediction of human serum albumin-drug binding affinity without albumin. Anal. Chim. Acta, 2002, 454, 101-108.
85. Du, S. L.; Xie, Y. X.; Chen, X. Q. Influence of glucose on the human serum albumin-flavone interaction and their antioxidant activity. Mol. BioSyst., 2013, 9, 55-60.
86. Xie, Y. X.; Xiao, J. B.; Kai, G. Y.; Chen, X. Q. Glycation of plasma proteins in type II diabetes lowers the non-covalent interaction affinities for dietary polyphenols. Integr. Biol., 2012, 4, 502-507.
87. Xiao, J. B.; Xie, Y. X.; Wang, Y. L.; Cao, H.; Chen, X. Q. Glycation of plasma proteins in diabetics will reduce benefits of antioxidant capacity of natural polyphenols. Free Radic. Biol. Med., 2012, 53(S2), S90.
88. Xiao, J. B.; Xie, Y. X.; Cao, H.; Chen, X. Q. Diabetes can diminish benefits of free radical scavenging potential of polyphenols in blood. Free Rad. Biol. Med., 2012, 53(S1), S67.
89. Joseph, K. S.; Anguizola J.; Jackson A. J. and Hage D. S. Chromatographic analysis of acetohexamide binding to glycated human serum albumin. J Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2010, 878, 2775-2781.
90. Joseph, K. S.; Anguizola, J.; Hage, D. S. Binding of tolbutamide to glycated human serum albumin. J. Pharm. Biomed. Anal., 2011, 54, 426-432.
91. Basiaga, S. B. G.; Hage, D. S. Chromatographic studies of changes in binding of sulfonylurea drugs to human serum albumin due to glycation and fatty acids. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2010, 878, 3193-3197.
92. Trynda-Lemiesz, L.; Wiglusz K. Effects of glycation on meloxicam binding to human serum albumin. J. Mol. Struct., 2011, 995, 35-40.
93. Matsuda, R.; Anguizola, J.; Joseph, K. S.; Hage, D. S. Analysis of drug interactions with modified proteins by high-performance affinity chromatography: Binding of glibenclamide to normal and glycated human serum albumin. J. Chromatogr. A, 2012, 1265, 114-122.
94. Joseph, K. S.; Hage, D. S. The effects of glycation on the binding of human serum albumin to warfarin and l-tryptophan. J. Pharm. Biomed. Anal., 2010, 53, 811-818.
95. Matsuda R.; Anguizola J.; Joseph, K. S.; Hage D. S. Highperformance affinity chromatography and the analysis of drug interactions with modified proteins: binding of gliclazide with glycated human serum albumin. Anal. Bioanal. Chem., 2011, 401, 2811-2819.
96. Henoumont, C.; Laurent S.; Muller, R. N.; Elst L. V. Effect of nonenzymatic glycosylation on the magnetic resonance imaging (MRI) contrast agent binding to human serum albumin. J. Med. Chem., 2012, 55, 4015-4019.
97. Peng, X. F.; Ma, J. Y.; Chen, F.; Wang, M. F. Naturally occurring inhibitors against the formation of advanced glycation endproducts. Food Funct., 2011, 2, 289-301.
98. Yamazaki, E.; Inagaki, M.; Kurita, O.; Inoue, T. Kinetics of fatty acid binding ability of glycated human serum albumin, J. Biosci., 2005, 30, 475-481.
99. Nakajou, K.; Watanabe, H.; Kragh-Hansen, U.; Maruyama, T.; Otagiri, M. The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants, Biochim. Biophys. Acta., 2003, 1623, 88-97.
100. Bourdon, E.; Loreau, N.; Blache, D. Glucose and free radicals impair the antioxidant properties of serum albumin, FASEB J., 1999, 13, 233-244.
101. Worner, W.; Pfleiderer, S.; Kratzer, W.; Rietbrock, N. Nonenzymatic glycation of human serum albumin: influence on the binding kinetics of the benzodiazepine binding sites. J. Clin. Chem. Clin. Biochem., 1990, 28, 527-531.
102. Xiao, J. B.; Chen, T. T.; Cao, H. Flavonoid glycosylation and biological benefits. Biotechnol. Adv., 2014. [Epub ahead of print].
103. Xie, Y. X.; Chen X. Q. Structures required of polyphenols for inhibiting advanced glycation end products formation. Curr. Drug Metab., 2013, 14, 414-431.
104. Xiao, J. B.; Högger, P. Dietary polyphenols and type 2 diabetes: current insights and future perspectives. Curr. Med. Chem., 2014. [Epub ahead of print].
105. Liu L. H.; Xie Y. X.; Song Z. Q.; Shang S. B.; Chen X. Q. Influence of dietary flavonoids on the glycation of plasma proteins. Mol. Biosyst., 2012, 8, 2183-2187.
106. Liu, H. Y.; Liu, H. W.; Wang, W.; Khoo, C.; Taylor, J.; Gu, L. W. Cranberry phytochemicals inhibit glycation of human hemoglobin and serum albumin by scavenging reactive carbonyls. Food Funct., 2011, 2, 475-482.
107. Lee, I. S.; Kim, I. S.; Lee, Y. M.; Lee, Y.; Kim, J. H.; Kim, J. S. 2', 4'-O-diacetylquercitrin, a novel advanced glycation end-product formation and aldose reductase inhibitor from Melastoma sanguineum. Chem. Pharmaceut. Bull., 2013, 61, 662-665.
108. Wu, Q.; Chen, H.; Lv, Z.; Li, S.; Hu, B.; Guan, Y.; Xie, B.; Sun, Z. Oligomeric procyanidins of lotus seedpod inhibits the formation of advanced glycation end-products by scavenging reactive carbonyls. Food Chem., 2013, 138, 1493-1502.